Search
Febuxostat
go.drugbank.com/drugs/DB04854ApprovedInvestigationalFebuxostat is a non-purine xanthine oxidase (XO) inhibitor. … [L32238] Gout is a form of arthritis that is caused by the accumulation of uric acid crystal in or around a joint, leading to inflammation and further deposition of uric acid crystal deposition in bones
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesSynonyms: 2-(3-cyano-4-isobutoxyphenyl)-4-methyl- 1,3-thiazole-5-carboxylic acidDronedarone
go.drugbank.com/drugs/DB04855ApprovedInvestigational[T28] Commonly marketed as Multaq®, dronedarone was approved by the FDA in July 2009 and Health Canada in August 2009. … A safety concern for the risk of drug-induced hepatocellular injury has been issued following marketing of dronedarone.[L8800]
Categories: Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: N-(2-butyl-3-(4-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)-methanesulfonamide, N-(2-butyl-3-(p-(3-(dibutylamino)propoxy)benzoyl)-5-benzofuranyl)methanesulfonamideDexloxiglumide
go.drugbank.com/drugs/DB04856InvestigationalDexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist in phase III testing by Rottapharm in Europe only, as U.S. trials have been discontinued. … As the D-isomer of loxiglumide, it retains all pharmacological properties of loxiglumide but is more potent.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesLefradafiban
go.drugbank.com/drugs/DB04863InvestigationalLefradafiban is an oral platelet glycoprotein IIb/IIIa receptor antagonist being investigated in the treatment of angina.
Categories: Heterocyclic Compounds, 1-RingLintitript
go.drugbank.com/drugs/DB04867ExperimentalLintitript is a new, highly specific and potent CCK-A receptor antagonist.
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingLorcaserin
go.drugbank.com/drugs/DB04871ApprovedInvestigationalWithdrawnThis decision was based on the results of a clinical trial assessing the risk of heart-related problems that found that patients treated with lorcaserin may have a higher risk of cancer. … Lorcaserin is marketed as a salt form called Belviq, which is lorcaserin hydrochloride.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-RingPicoplatin
go.drugbank.com/drugs/DB04874InvestigationalPicoplatin is a cytotoxic platinum compound in clinical development for the treatment of patients with solid tumors.
Synonyms: (SP-4-3)-Amminedichloro(2-methylpyridine)platiniumPralnacasan
go.drugbank.com/drugs/DB04875ExperimentalPralnacasan is an orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE).
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingVoacamine
go.drugbank.com/drugs/DB04877ExperimentalVoacamine is an alkaloid isolated from the bark of the Pescheria fuchsiae folia tree. It is an antimalarial drug approved for use in several African countries. Voacamine is also under investigation for use in modulating multidrug-resista...
Categories: P-glycoprotein inhibitors, Heterocyclic Compounds, 2-RingCalanolide A
go.drugbank.com/drugs/DB04886InvestigationalCalanolide A is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) derived from a plant found in the Malaysian rain forest. A related compound, calanolide B, also has anti-HIV activity. … A preliminary dosing study among HIV-infected individuals showed a significant antiviral effect compared with placebo.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingSynonyms: Calanolide A, (+)-calanolide A